A Phase 3, Double-blind, Randomized Study of RVT-101 Versus Placebo When Added to Existing Stable Donepezil Treatment in Subjects With Mild to Moderate Alzheimer's Disease

Trial Profile

A Phase 3, Double-blind, Randomized Study of RVT-101 Versus Placebo When Added to Existing Stable Donepezil Treatment in Subjects With Mild to Moderate Alzheimer's Disease

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Oct 2017

At a glance

  • Drugs Intepirdine (Primary)
  • Indications Alzheimer's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms MINDSET
  • Sponsors Axovant Sciences
  • Most Recent Events

    • 26 Sep 2017 Primary endpoint has not been met. (Change from baseline on Alzheimers Disease Cooperative Study - Activities of Daily Living (ADCS-ADL) scale)
    • 26 Sep 2017 Primary endpoint has not been met. (Change from baseline on Alzheimers Disease Assessment Scale - Cognitive Subscale 11 items (ADAS-Cog-11))
    • 26 Sep 2017 Topline results published in an Axovant Sciences media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top